Engineering High-Speed Pen Injector Final Assembly Machine: Solving the Cartridge Press-Fit Challenge

In the lifecycle of a pen injector, final assembly is where the stakes are highest. Unlike pre-assembly, where ejected units consist only of low-cost injection-molded plastic components, a failure at the final assembly stage means losing a pre-filled drug cartridge worth several dollars. For GLP-1 receptor agonists, insulin biosimilars, and other high-value biologics, that figure can climb significantly higher. When a final assembly line operates at speeds of 160 pens per minute (ppm), even a modest reject rate of 1% translates into substantial financial loss and wasted API over a production shift.^1,2

This economic reality demands a fundamentally different engineering philosophy for pen injector final assembly. Speed alone is not the objective; first-pass yield is the ultimate metric of success. Every design decision, from machine architecture and servo control to sensor selection and data architecture, must be evaluated against a single question: does this reduce the probability of rejecting a unit that contains a live drug cartridge?

This article examines the engineering principles behind high-speed pen injector final assembly systems, with particular focus on the cartridge press-fit operation, which represents the single most crucial, and most failure-prone, step in the entire process. By exploring modular architecture, real-time force-displacement monitoring, multi-point dimensional verification, and stringent data integrity protocols, this article defines the technical requirements for achieving greater than 99.5% first-pass yield in commercial-scale production.^1,2

Why Final Assembly Is the Highest-Risk Stage

A pen injector final assembly line receives 2 categories of input: the pre-assembled pen mechanism (comprising the housing, dosing engine, and drive sleeve) and the pre-filled drug cartridge (typically a 3 mL glass or polymer barrel). The primary function of the line is to marry these 2 elements, verify functional performance, and produce a finished device ready for labeling and secondary packaging.

The risk profile of this operation is inherently asymmetric. A pre-assembled pen mechanism rejected at an earlier stage costs only a fraction of a dollar. However, the moment a drug cartridge is introduced into the assembly sequence, the cost of rejection multiplies by an order of magnitude. The cartridge contains a filled and stoppered barrel, a crimped aluminum cap, and a precisely measured volume of API. None of these components can be recovered or reworked once the cartridge enters the press-fit station.^1,2

This asymmetry shapes every aspect of final assembly engineering. The line must be designed not merely to assemble quickly, but to assemble correctly on the first attempt, every time. The tolerance for process variation is effectively zero. Furthermore, the handling of the cartridge must be gentle enough to prevent cosmetic damage to the aluminum cap or particulate generation from the rubber stopper, while still maintaining the rigid positional control required for high-speed automation.³

Modular Architecture: Building Around the Critical Node

Conventional assembly line design often distributes stations linearly, treating each operation as roughly equivalent in importance. For pen injector final assembly, this approach is inadequate. The cartridge press-fit operation is not simply 1 station among many, it is the critical node around which the entire system must be architected.

A modular multi-cell architecture addresses this requirement effectively. Rather than a single monolithic line, the system is organized into discrete functional cells, each optimized for a specific phase of the assembly process.²

The 2-Cell Approach

A typical high-speed configuration employs 24 stations distributed across 2 primary cells, achieving stable output rates of 160 ppm while maintaining the process control density required for pharmaceutical-grade assembly:²

1. Cell 1: preparation and orientation. This cell handles the feeding, orientation, and inspection of the incoming pre-assembled pen bodies and drug cartridges. Crucially, it must use zero-contact or low-friction feeding mechanisms (such as specialized conveyor systems rather than traditional vibratory bowls) to prevent thermal excursions or particulate generation that could compromise the biologic drug product.
2. Cell 2: Press-fit and verification. This cell manages the press-fit operation itself, with dedicated stations for force monitoring, dimensional verification, and functional testing.

This modularity offers several distinct engineering advantages. First, it allows the press-fit cell to operate with tighter environmental controls and more sophisticated instrumentation than would be practical across an entire line. Second, it enables independent installation qualification and operational qualification of each cell, simplifying the overall good manufacturing practice (GMP) documentation burden and accelerating the factory acceptance test schedule. Third, it provides a natural framework for scaling, additional cells can be integrated to increase throughput without redesigning the core system architecture.²

The Cartridge Press-Fit: Engineering for Zero Defects

The cartridge press-fit operation is deceptively simple in concept: insert a glass or polymer cartridge into the pen housing until it seats firmly against a mechanical stop. In practice, this operation concentrates nearly all of the critical failure modes in final assembly.^3,4

The cartridge is a fragile, high-value component. Excessive force during insertion can induce micro-cracks in the glass barrel. These defects may not be visible to standard optical inspection systems but can propagate under storage conditions or during patient use, leading to leakage, loss of sterility, or complete device failure. Conversely, insufficient force results in an incompletely seated cartridge, which compromises dose accuracy and may cause mechanical jamming during injection.^3,4

The engineering challenge is compounded by inherent material variability. Glass cartridges exhibit dimensional tolerances that, although within ISO specifications, create measurable variation in insertion force requirements from unit to unit. Rubber stoppers and aluminum crimp caps introduce additional friction variables. The press-fit system must accommodate this natural variation while maintaining absolute control over the force applied to each individual unit.

Real-Time Force-Displacement Curve Monitoring

The solution to the press-fit challenge lies in continuous force-displacement curve monitoring throughout the entire insertion stroke. Rather than relying on simple peak-force thresholds, which cannot distinguish between a properly seated cartridge and one that has encountered an obstruction midway through the stroke, the system captures the complete force profile as a function of displacement.

Each press-fit operation generates a characteristic curve. A properly executed insertion produces a predictable force signature: initial contact, progressive resistance as the cartridge engages the housing bore, and a defined force peak at final seating. Deviations from this expected profile, such as an unexpected force spike indicating a micro-crack, a plateau suggesting misalignment, or an incomplete curve indicating premature stoppage, trigger immediate rejection.

To achieve this level of control at 160 ppm, the system requires high-resolution piezoelectric force sensors paired with precision servo motors. These sensors provide the measurement bandwidth necessary to capture transient force events that occur on millisecond timescales. The press-fit operation completes in well under 1 second; only sensors with sufficient dynamic response can reliably detect the brief force anomalies that indicate cartridge damage.²

The acceptable force-displacement envelope is established during process validation and locked under electronic change control. Any modification to the envelope parameters requires formal deviation procedures, ensuring that the validated process cannot be inadvertently altered during production runs.²

Multi-Point Dimensional Verification for Dose Accuracy

Force monitoring alone, although necessary to prevent damage, is not sufficient to guarantee dose accuracy in the finished device. The functional performance of a pen injector depends on precise geometric relationships between the cartridge, the dosing mechanism, and the drive components. Even microscopic deviations in cartridge seating depth can alter the effective stroke length of the plunger rod, directly affecting the delivered dose volume.

Linear variable differential transformers (LVDTs) provide the measurement precision required for post-assembly dimensional verification. These sensors offer micron-level resolution and excellent long-term stability, characteristics that make them superior to optical sensors for in-line pharmaceutical applications in which measurement drift is unacceptable.²

A robust multi-point LVDT verification strategy measures critical dimensions at several locations on the assembled device:

• Plunger rod protrusion: Verifying the exact position of the plunger rod relative to the pen body.
• Cartridge seating depth: Confirming the cartridge is fully seated against the internal mechanical stops.
• Overall assembled length: Ensuring all components are properly mated.

Each measurement is verified against validated acceptance criteria. Units that fall outside the specified dimensional envelope are rejected before proceeding to functional testing, preventing the waste of additional test resources on devices that cannot meet International Organization for Standardization (ISO) 11608 performance specifications.

The combination of force-displacement monitoring during assembly and LVDT dimensional verification after assembly creates a layered quality assurance strategy. The first layer prevents damage; the second confirms correct geometry. Together, they provide high confidence that every unit reaching the functional test station can deliver accurate doses.²

Unit-Level Traceability and 21 CFR Part 11 Compliance

At a line speed of 160 pens per minute, a final assembly system produces over 230,000 units in a single 24-hour production day. Regulatory expectations, particularly under FDA 21 Code of Federal Regulations Part 11 and EU GMP Annex 11, require that complete process data be attributable to each individual unit, stored securely, and available for review throughout the product lifecycle.^5,6

Radiofrequency identification-based pallet identification systems provide the foundation for unit-level traceability. Each transport pallet or nest position carries a unique identifier that links the physical unit to its complete digital process record. As the unit progresses through each station, process parameters, force curves, dimensional measurements, test results, timestamps, and operator actions, are automatically associated with that identifier in the supervisory control and data acquisition (SCADA) system.

This approach eliminates the data integrity risks inherent in traditional batch-level recording systems. If a quality investigation requires examination of a specific unit's assembly history, the complete record can be retrieved without ambiguity. The system maintains a continuous, auditable chain of custody from cartridge insertion through final packaging.^5,6

Electronic records are protected by stringent role-based access controls, comprehensive audit trails that capture all data modifications, and automated backup procedures. The control system architecture ensures that process data cannot be altered or deleted without generating a permanent, traceable record of the change, a fundamental requirement for pharmaceutical manufacturing systems.^5-7

Managing Utility Interruptions: The Conservative Approach

An aspect of final assembly system design that is often overlooked is the response to utility interruptions, power failures, compressed air loss, or emergency stops. In a system in which each unit in process contains a high-value drug cartridge, the consequences of an uncontrolled shutdown extend beyond simple production loss.

The engineering principle for managing utility interruptions in final assembly is straightforward but highly conservative: upon any utility failure, all units currently within the active assembly system are automatically classified as rejected.

No attempt is made to determine which units may have been unaffected by the sudden loss of air pressure or servo control. The economic cost of scrapping several dozen in-process units is trivial compared with the regulatory and patient safety risk of releasing a potentially compromised device.

To protect the data associated with these events, uninterruptible power supply (UPS) systems are integrated into the control architecture. The UPS protects data integrity during power events, ensuring that batch records and audit trails are properly closed and saved before the programmable logic control and SCADA systems shut down. Upon power restoration, the system executes a controlled restart sequence that requires operators to clear all in-process material before resuming normal production.

This conservative approach reflects a broader design philosophy: in pharmaceutical final assembly, the cost of a false acceptance always exceeds the cost of a false rejection.

Achieving First-Pass Yields

High-speed pen injector final assembly is not simply a faster version of manual assembly. It is a distinct engineering discipline that requires purpose-built architecture, advanced process monitoring, and rigorous data management, all designed around the central reality that every rejected unit carries the cost of a lost drug cartridge.

The convergence of real-time force-displacement monitoring, multi-point LVDT dimensional verification, and unit-level digital traceability enables modern assembly systems to achieve the first-pass yields that pharmaceutical economics demand. As the global market for GLP-1 therapies and insulin biosimilars continues to expand rapidly, the ability to deploy these systems quickly and validate them efficiently will increasingly determine which manufacturers can meet growing demand without compromising quality or profitability.⁴

The engineering challenge of the cartridge press-fit is substantial, but it is solvable provided the system is designed from the outset with the understanding that in final assembly, precision is not a luxury. It is the minimum requirement for success.

References

1. Xu J. The Complete Technical Guide to Injection Pen Assembly Lines: Pre-Assembly, Final Assembly, Functional Testing, and GMP Validation. Drofen Machinery, 2026. https://www.drofen-pharma.com/info/the-complete-technical-guide-to-injection-pen-103559400.html
2. Xu J. Complete engineering guide: Selecting and implementing high-speed pen injector final assembly systems. Drofen Machinery, 2026. https://www.drofen-pharma.com/info/injector-final-assembly-machine-103542062.html
3. ISO 11608-1:2022. Needle-based injection systems for medical use — Requirements and test methods — Part 1: Needle-based injection systems. International Organization for Standardization.
4. FDA. Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products. Guidance for Industry, US Food and Drug Administration, 2023.
5. 21 CFR Part 11 — Electronic Records; Electronic Signatures. Code of Federal Regulations, Title 21. FDA.
6. EudraLex Volume 4, Annex 11: Computerised Systems. EU Guidelines for Good Manufacturing Practice, European Commission. 2011.
7. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. International Society for Pharmaceutical Engineering, ISPE. 2022.

About the Author

Jordan Xu is managing director at Drofen Machinery Equipment Co., Ltd., a turnkey system supplier of automated assembly lines for injection pens and pre-filled syringes for global pharmaceutical manufacturers and contract development and manufacturing organizations.